These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 10182193)

  • 1. Cost effectiveness of coronary heart disease prevention strategies in adults.
    Brown AD; Garber AM
    Pharmacoeconomics; 1998 Jul; 14(1):27-48. PubMed ID: 10182193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The health economics of the treatment of hyperlipidemia and hypertension.
    McMurray J
    Am J Hypertens; 1999 Oct; 12(10 Pt 2):99S-104S. PubMed ID: 10555609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin cost-effective?
    Perreault S; Hamilton VH; Lavoie F; Grover S
    Arch Intern Med; 1998 Feb; 158(4):375-81. PubMed ID: 9487235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease.
    Goa KL; Barradell LB; McTavish D
    Pharmacoeconomics; 1997 Jan; 11(1):89-110. PubMed ID: 10172918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease: evaluative study carried out in Spain.
    Plans-Rubió P
    Pharmacoeconomics; 1998 May; 13(5 Pt 2):623-43. PubMed ID: 17165328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost and effectiveness of adherence-improving interventions for antihypertensive and lipid-lowering drugs*.
    Chapman RH; Ferrufino CP; Kowal SL; Classi P; Roberts CS
    Int J Clin Pract; 2010 Jan; 64(2):169-81. PubMed ID: 20089007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The modeled lifetime cost-effectiveness of published adherence-improving interventions for antihypertensive and lipid-lowering medications.
    Chapman RH; Kowal SL; Cherry SB; Ferrufino CP; Roberts CS; Chen L
    Value Health; 2010; 13(6):685-94. PubMed ID: 20825627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.
    Hay JW; Sterling KL
    Pharmacoeconomics; 2005; 23(2):133-41. PubMed ID: 15748088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.
    Pickin DM; McCabe CJ; Ramsay LE; Payne N; Haq IU; Yeo WW; Jackson PR
    Heart; 1999 Sep; 82(3):325-32. PubMed ID: 10455083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemfibrozil cost-benefit study. Targeting subgroups for effective hyperlipidaemia drug therapy.
    Sarma S; Fifer SK
    Drugs; 1990; 40 Suppl 1():42-52. PubMed ID: 2127008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis in heart disease, Part II: Preventive therapies.
    Kupersmith J; Holmes-Rovner M; Hogan A; Rovner D; Gardiner J
    Prog Cardiovasc Dis; 1995; 37(4):243-71. PubMed ID: 7831469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economics of lipid lowering in primary prevention: lessons from the West of Scotland Coronary Prevention Study.
    Shepherd J
    Am J Cardiol; 2001 Mar; 87(5A):19B-22B. PubMed ID: 11256845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the US.
    Rosen VM; Taylor DC; Parekh H; Pandya A; Thompson D; Kuznik A; Waters DD; Drummond M; Weinstein MC
    Pharmacoeconomics; 2010; 28(1):47-60. PubMed ID: 20014876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
    Hamilton VH; Racicot FE; Zowall H; Coupal L; Grover SA
    JAMA; 1995 Apr; 273(13):1032-8. PubMed ID: 7897787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can we afford to treat hyperlipidaemia as we should? Strategies for rational treatment.
    Durrington PN
    Atherosclerosis; 1998 Sep; 139 Suppl 1():S1-5. PubMed ID: 9811152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.
    De Smedt D; Kotseva K; De Bacquer D; Wood D; De Backer G; Dallongeville J; Seppo L; Pajak A; Reiner Z; Vanuzzo D; Georgiev B; Gotcheva N; Annemans L
    Eur Heart J; 2012 Nov; 33(22):2865-72. PubMed ID: 22843446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
    Coukell AJ; Wilde MI
    Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronary heart disease prevention: insights from modelling incremental cost effectiveness.
    Marshall T
    BMJ; 2003 Nov; 327(7426):1264. PubMed ID: 14644970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria.
    Lim SS; Vos T; Peeters A; Liew D; McNeil JJ
    Med J Aust; 2001 Nov; 175(9):459-64. PubMed ID: 11758073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.